Interventions that enhance SIGMAR1 activity or directly increase POM121 function, such as the use of SIGMAR1 agonists such as pridopidine or fluvoxamine, have shown promise in restoring normal nucleocytoplasmic transport and autophagy, and may provide therapeutic benefits for patients with ALS (Wang et al. 2023c). Here, POM121 is linked to amyotrophic lateral sclerosis.